Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)

Clinical trial NCT06475781 · RECRUITING

Trial details

NCT number: NCT06475781
Sponsor: Foresee Pharmaceuticals Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Group 3 Pulmonary Hypertension

Start date: 2025-03-01
Primary completion: 2028-02-01
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.